Related Experiment Videos
New approach to protein-losing gastroenteropathy
Lymphology
|March 1, 1979
Summary
Increased gastrointestinal mucosal fibrinolysis is linked to protein-losing gastroenteropathy in certain conditions. Antifibrinolytic therapy with tranexamic acid effectively treated patients with elevated fibrinolysis.
Area of Science:
- Gastroenterology
- Hematology
- Pathophysiology
Background:
- Protein-losing gastroenteropathy (PLG) is characterized by excessive protein loss into the gastrointestinal tract.
- The underlying mechanisms of PLG, particularly the role of mucosal fibrinolysis, require further elucidation.
Purpose of the Study:
- To investigate fibrinolytic activity in the gastrointestinal mucosa of patients with PLG.
- To evaluate the therapeutic efficacy of antifibrinolytic therapy in PLG associated with increased mucosal fibrinolysis.
Main Methods:
- Biopsied gastrointestinal mucosa was analyzed for fibrinolytic activity.
- Patients received antifibrinolytic therapy with tranexamic acid.
Main Results:
- Elevated mucosal fibrinolytic activity was observed in PLG patients with erosive gastritis, Menetrier's disease, atrophic gastritis, or Crohn's disease.
- Patients with intestinal lymphangiectasia exhibited normal mucosal fibrinolysis.
- Tranexamic acid therapy demonstrated significant therapeutic effects in patients with increased mucosal fibrinolysis.
Conclusions:
- Increased gastrointestinal mucosal fibrinolysis is implicated in specific forms of PLG.
- Tranexamic acid is effective in managing PLG by interrupting a cycle of membrane disorder, increased fibrinolysis, vascular permeability, and hypoproteinemia.